Quotient Sciences Begins Clinical Trial for AI Designed Drug Formulation

May 28, 2026
Quotient Sciences has started a Phase I clinical study of an oral drug formulation created using artificial intelligence, following approval from the UK’s Medicines and Healthcare products Regulatory Agency.

Quotient Sciences has begun a Phase I clinical study of a new oral drug formulation created using artificial intelligence, announced in a press release. The trial received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and is being conducted at the company’s UK facility.

The study will evaluate the safety and pharmacokinetics of the formulation in healthy volunteers. It aims to validate the use of AI for drug product development and demonstrate how AI can accelerate formulation design and decision making.

Quotient Sciences used a machine learning algorithm from Intrepid Labs to support formulation design and optimization. This approach allowed rapid exploration of formulation options and data informed decision making to improve expected clinical performance.

The company described this as the first reported instance of an AI designed formulation entering clinical evaluation. It plans to expand its integration of AI across formulation development and clinical workflows, with further updates expected in the coming months.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Guide
Specialist Ambient Medical Scribe Vendors

Specialist Ambient Medical Scribe Vendors

AI scribes that turn medical consultations into draft clinical notes

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.